Sonata Therapeutics
Sonata Therapeutics is a biotech company specializing in the development of Network Medicines to treat complex diseases like cancer and fibrosis by reprogramming diseased cells.
About Sonata Therapeutics
Sonata Therapeutics is pioneering the development of Network Medicines, a novel class of therapeutics aimed at reprogramming diseased cells to guide multicellular networks toward resolving various diseases. The company focuses on conditions such as cancer and fibrosis, where the role of multicellular networks is critical in disease progression.
Diseases Targeted by Sonata Therapeutics
Sonata Therapeutics concentrates on diseases where multicellular networks significantly affect disease progression, including cancer and fibrosis. By focusing on the intricate interactions within these networks, Sonata aims to develop therapies that can effectively address these complex diseases.
Know, Don’t Guess Platform
Sonata Therapeutics utilizes its proprietary drug development platform named 'Know, Don’t Guess'. This platform systematically assesses Network Effects to refine target selection and enhance the development of effective therapies. The aim is to improve the precision and efficacy of treatments for complex diseases.
Collaboration with Champalimaud Foundation
Sonata Therapeutics has entered a research collaboration with the Champalimaud Foundation to advance SNT-3012, a therapeutic targeting pancreatic and colorectal cancers. This partnership leverages Sonata's expertise in Network Medicines to tackle these specific types of cancer.
SITC 2023 Presentation
Sonata Therapeutics presented supporting data for its Network Medicines approach at the Society for Immunotherapy of Cancer (SITC) 2023. This presentation showcased the potential efficacy of their therapeutics in reprogramming diseased cells and contributed to the company's visibility within the scientific community.